De Novo Resistance and Relapse from Daratumumab Monotherapy in NDMM Is Associated with Immune Evasion and Immunosuppression
Mark B. Meads(Moffitt Cancer Center), Kenneth H. Shain(Moffitt Cancer Center), Samer Sansil(Moffitt Cancer Center), Alexandra Achille(Moffitt Cancer Center), Ciara L. Freeman(Moffitt Cancer Center), Sean Yoder(Moffitt Cancer Center), Ariosto Siqueira Silva(Moffitt Cancer Center), Chaomei Zhang(Moffitt Cancer Center), Rachid Baz(Moffitt Cancer Center), Sonila Toska(Moffitt Cancer Center), Ariel Grajales‐Cruz(Moffitt Cancer Center), Brandon Blue(Moffitt Cancer Center), Melissa Alsina(Moffitt Cancer Center), Xiaohong Zhao(Xidian University), Xiaofei Song(Jiangsu University), Jongphil Kim(Moffitt Cancer Center), David Noyes(Moffitt Cancer Center), Praneeth Sudalagunta(Moffitt Cancer Center)
Cited by 1
Related Papers
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma
|New England Journal of Medicine|2022|457
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
|Leukemia|2017|356
Reanalysis of Clinical Exome Sequencing Data
|New England Journal of Medicine|2019|303
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|282